{"id":55083,"date":"2022-09-30T00:01:19","date_gmt":"2022-09-30T00:01:19","guid":{"rendered":"https:\/\/elpais.com\/ciencia\/2022-09-30\/estados-unidos-aprueba-un-medicamento-contra-la-ela-pese-a-las-dudas-sobre-su-eficacia.html"},"modified":"2022-09-30T00:01:19","modified_gmt":"2022-09-30T00:01:19","slug":"estados-unidos-aprueba-un-medicamento-contra-la-ela-pese-a-las-dudas-sobre-su-eficacia","status":"publish","type":"post","link":"https:\/\/forocilac.org\/en\/estados-unidos-aprueba-un-medicamento-contra-la-ela-pese-a-las-dudas-sobre-su-eficacia\/","title":{"rendered":"The United States approves a drug against ALS despite doubts about its effectiveness"},"content":{"rendered":"<p>Estados Unidos ha aprobado la comercializaci\u00f3n de Relyvrio, un medicamento para el tratamiento de pacientes con esclerosis lateral amiotr\u00f3fica (ELA), una enfermedad incurable, seg\u00fan <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-option-patients-als\" >ha anunciado la Administraci\u00f3n de Alimentos y Medicamentos (FDA, por sus siglas en ingl\u00e9s)<\/a>. El regulador farmac\u00e9utico ha dado su visto bueno al medicamento a pesar de las dudas sobre su eficacia sin esperar al resultado de un ensayo cl\u00ednico m\u00e1s amplio, dada la falta de alternativas. Los ensayos con Relyvrio han sido financiados en parte con <a href=\"https:\/\/elpais.com\/elpais\/2016\/07\/28\/videos\/1469703244_643126.html\">los fondos obtenidos con el reto del <i>ice bucket,<\/i><\/a> que se convirti\u00f3 en viral hace unos a\u00f1os.<\/p>\n<p><a href=\"https:\/\/elpais.com\/ciencia\/2022-09-30\/estados-unidos-aprueba-un-medicamento-contra-la-ela-pese-a-las-dudas-sobre-su-eficacia.html\" >Keep reading<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The patients advocated for its approval due to the lack of alternatives for the disease<\/p>","protected":false},"author":1650,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[123],"tags":[],"class_list":{"0":"post-55083","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-portal"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/55083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/users\/1650"}],"replies":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/comments?post=55083"}],"version-history":[{"count":1,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/55083\/revisions"}],"predecessor-version":[{"id":55084,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/55083\/revisions\/55084"}],"wp:attachment":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/media?parent=55083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/categories?post=55083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/tags?post=55083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}